Schedule 13G filed Oct 6. Who filed, the stake, and how it changed.

Filed Oct 6. Who filed, the stake, and how it changed.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Click to view the official SEC document.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Neurogene's options match its Sept. 1 closing price and vest monthly after the first anniversary, subject to continued employment through vesting.

Neurogene (NASDAQ:NGNE – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.42) by ($0.11), FiscalAI reports. Neurogene Stock Performance NGNE stock opened at $34.54 on Tuesday. Neurogene has a fifty-two week low of $15.93 and a fifty-two [...]

Click to view the official SEC document.

Neurogene (Nasdaq: NGNE) reported second quarter 2026 results and progress on its NGN-401 Rett syndrome gene therapy. Phase 1/2 data (N=10) showed 100% of participants improved on CGI-I and gained ≥1 developmental milestone, averaging 4.7 milestones, with continued gains through 30 months and no plateau or milestone loss as of June 16, 2026.According to Neurogene, 7 of 10 participants gained ≥2 milestones and improved across ≥2 Rett domains, with significant benefits on RSGMS and RSHFS (p<0.001). NGN-401 was generally well-tolerated at 1E15 vg in 35 participants across trials as of August 10, 2026. All 25 Embolden registrational trial participants have been dosed, with topline data expected in 2H 2027, and a PPQ manufacturing campaign initiated in July 2026 to support a planned BLA, with PPQ runs targeted for completion by year-end 2026.The company completed an oversubscribed follow-on offering for approximately $144 million in gross proceeds. Cash, cash equivalents and short-term investments were $225.4 million at June 30, 2026, rising to a pro forma $360.2 million with July offering proceeds, which Neurogene expects to fund operations into 1Q 2029. Second quarter 2026 R&D and G&A expenses were $25.5 million and $11.2 million, respectively, and net loss was $34.5 million.

Neurogene (Nasdaq: NGNE) announced that its Board’s Compensation Committee approved non-qualified stock option inducement grants covering an aggregate of 12,555 shares of common stock for four new employees, effective August 3, 2026, under the company’s 2025 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).According to Neurogene, the options have an exercise price equal to the closing price on the grant date. The awards vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment.

Newleos Therapeutics, a clinical-stage biotech focused on neuropsychiatric disorders, appointed Rohan Palekar to its Board of Directors and elected him Chairman. Christoph Westphal, who has served as Executive Chairman since Newleos’ founding, will step down from that role but remain on the Board representing founding investor Longwood Fund.According to Newleos, Palekar brings over 30 years of biotechnology and pharmaceutical experience, including serving as founding CEO of 89bio, where he led multiple programs from preclinical through Phase 3 in liver and cardiometabolic diseases; 89bio was acquired by Roche in 2025 for up to $3.5 billion. He previously was President and CEO of Avanir Pharmaceuticals, which was acquired by Otsuka Pharmaceutical in 2015, and Chief Commercial Officer at Medivation, after senior roles at Johnson & Johnson. Newleos highlights his CNS and company-building background as it approaches key clinical inflection points in ongoing anxiety trials. Palekar also serves on the board of Neurogene (Nasdaq: NGNE) and previously served on Neoleukin Therapeutics’ board.

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

The biotech is selling 3.5M shares at $30 each, plus pre-funded warrants. Underwriters also have a 30-day option for 624,999 more shares.

Shares or pre-funded warrants will be sold, with underwriters getting a 30-day option. Proceeds fund NGN-401 development, pre-commercial work and working capital.

Click to view the official SEC document.

All 10 patients improved on CGI-I, with gains continuing through 30 months and no milestone loss. Embolden dosing is complete; topline data is due 2H 2027.